The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration

J. Lankelma, M. Stuurman, J. Van Hoogenhuijze, A. Van Bochove, J. B. Vermorken, J. Verweij, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

The pharmacokinetic plasma profile of mitomycin C (MMC) was studied during sequential courses in man. MMC was given repeatedly as i.v. bolus injections at fixed dose levels to the same patient either as a single agent or as part of different combination chemotherapy regimens. Large interindividual variations between the various pharmacokinetic parameters were observed. Statistical analysis showed no significant differences between average pharmacokinetic parameters when comparing the first and the second MMC injection, except for the total body clearance (Cltot). The Cltot was higher for the second injection when compared to the first injection in a group of patients who received MMC as a single agent (10 patients). For a group of patients receiving MMC as part of a combination therapy the average values of Cltot of the first when compared to the second injection were not statistically different (nine patients). This observation could not be correlated with clinical observations on toxicities.

Original languageEnglish (US)
Pages (from-to)175-180
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume24
Issue number2
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Mitomycin
Intravenous Administration
Pharmacokinetics
Injections
Proxy
Combination Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Lankelma, J., Stuurman, M., Van Hoogenhuijze, J., Van Bochove, A., Vermorken, J. B., Verweij, J., & Pinedo, H. M. (1988). The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration. European Journal of Cancer and Clinical Oncology, 24(2), 175-180. https://doi.org/10.1016/0277-5379(88)90249-0

The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration. / Lankelma, J.; Stuurman, M.; Van Hoogenhuijze, J.; Van Bochove, A.; Vermorken, J. B.; Verweij, J.; Pinedo, H. M.

In: European Journal of Cancer and Clinical Oncology, Vol. 24, No. 2, 1988, p. 175-180.

Research output: Contribution to journalArticle

Lankelma, J, Stuurman, M, Van Hoogenhuijze, J, Van Bochove, A, Vermorken, JB, Verweij, J & Pinedo, HM 1988, 'The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration', European Journal of Cancer and Clinical Oncology, vol. 24, no. 2, pp. 175-180. https://doi.org/10.1016/0277-5379(88)90249-0
Lankelma, J. ; Stuurman, M. ; Van Hoogenhuijze, J. ; Van Bochove, A. ; Vermorken, J. B. ; Verweij, J. ; Pinedo, H. M. / The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration. In: European Journal of Cancer and Clinical Oncology. 1988 ; Vol. 24, No. 2. pp. 175-180.
@article{76f53ee1cfd04a6bb4cbedc623e2aebe,
title = "The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration",
abstract = "The pharmacokinetic plasma profile of mitomycin C (MMC) was studied during sequential courses in man. MMC was given repeatedly as i.v. bolus injections at fixed dose levels to the same patient either as a single agent or as part of different combination chemotherapy regimens. Large interindividual variations between the various pharmacokinetic parameters were observed. Statistical analysis showed no significant differences between average pharmacokinetic parameters when comparing the first and the second MMC injection, except for the total body clearance (Cltot). The Cltot was higher for the second injection when compared to the first injection in a group of patients who received MMC as a single agent (10 patients). For a group of patients receiving MMC as part of a combination therapy the average values of Cltot of the first when compared to the second injection were not statistically different (nine patients). This observation could not be correlated with clinical observations on toxicities.",
author = "J. Lankelma and M. Stuurman and {Van Hoogenhuijze}, J. and {Van Bochove}, A. and Vermorken, {J. B.} and J. Verweij and Pinedo, {H. M.}",
year = "1988",
doi = "10.1016/0277-5379(88)90249-0",
language = "English (US)",
volume = "24",
pages = "175--180",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "2",

}

TY - JOUR

T1 - The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration

AU - Lankelma, J.

AU - Stuurman, M.

AU - Van Hoogenhuijze, J.

AU - Van Bochove, A.

AU - Vermorken, J. B.

AU - Verweij, J.

AU - Pinedo, H. M.

PY - 1988

Y1 - 1988

N2 - The pharmacokinetic plasma profile of mitomycin C (MMC) was studied during sequential courses in man. MMC was given repeatedly as i.v. bolus injections at fixed dose levels to the same patient either as a single agent or as part of different combination chemotherapy regimens. Large interindividual variations between the various pharmacokinetic parameters were observed. Statistical analysis showed no significant differences between average pharmacokinetic parameters when comparing the first and the second MMC injection, except for the total body clearance (Cltot). The Cltot was higher for the second injection when compared to the first injection in a group of patients who received MMC as a single agent (10 patients). For a group of patients receiving MMC as part of a combination therapy the average values of Cltot of the first when compared to the second injection were not statistically different (nine patients). This observation could not be correlated with clinical observations on toxicities.

AB - The pharmacokinetic plasma profile of mitomycin C (MMC) was studied during sequential courses in man. MMC was given repeatedly as i.v. bolus injections at fixed dose levels to the same patient either as a single agent or as part of different combination chemotherapy regimens. Large interindividual variations between the various pharmacokinetic parameters were observed. Statistical analysis showed no significant differences between average pharmacokinetic parameters when comparing the first and the second MMC injection, except for the total body clearance (Cltot). The Cltot was higher for the second injection when compared to the first injection in a group of patients who received MMC as a single agent (10 patients). For a group of patients receiving MMC as part of a combination therapy the average values of Cltot of the first when compared to the second injection were not statistically different (nine patients). This observation could not be correlated with clinical observations on toxicities.

UR - http://www.scopus.com/inward/record.url?scp=0023876384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023876384&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(88)90249-0

DO - 10.1016/0277-5379(88)90249-0

M3 - Article

C2 - 3128446

AN - SCOPUS:0023876384

VL - 24

SP - 175

EP - 180

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 2

ER -